Cross-validation of in vitro and in vivo assay systems for assessing P-gp interactions at the BBB
Written by Franciska Erdő and István Sziráki
P-gp (MDR1, ABCB1), a member of the ATP-binding cassette proteins, is the most important efflux transporter at the blood-brain barrier (BBB). Testing of P-gp mediated brain penetration and drug-drug interactions at the BBB is important to assess the toxic or therapeutic potential of drugs.The correlation between in vitro and in vivo data is often not satisfactory (Garberg et al., 2005) , therefore it is essential to employ in vivo tests along with in vitro assays.
The aim of our recent study (Sziráki et al, 2011) was to set up an integrated in vitro – in vivo test system for assessing P-gp related drug-drug interactions. We provided evidence that quinidine is a good probe substrate to study P-gp function at the BBB since it works well in in vitro assays with different complexity (membrane-based assays and monolayers), and also in vivo in microdialysis studies in rats and mice. Even more importantly our results show that quinidine and PSC-833 can serve as an excellent P-gp-specific probe substrate/inhibitor combination applicable to several assay systems both in vitro and in vivo.
Investigation of the barrier function of P-gp at the BBB requires a variety of in vitro and in vivo methods preferably using the same probe substrate and inhibitor. Digoxin (DGX) has been recommended as a probe substrate by the regulatory agencies (Zhang et al., 2009, Giacomini et al., 2010). Quinidine (QND) is also considered as a P-gp specific substrate (Kusuhara et al., 1997, Ma et al., 2010,). Monolayer efflux studies using MDR1-MDCKII have yielded negative results with some highly permeable compounds such as verapamil, ketoconazole and itraconazole (Polli et al., 2001). Yet, the distribution of these compounds across the BBB is controlled by P-gp in various animal models (Ishiwata et al., 2007, von Moltke, et al., 2004, Miyama et al., 1998) and also in humans (Sasongko et al., 2005).
We aimed to set up a validated and integrated assay system, and to provide further evidence that QND can be used as a probe substrate of P-gp at the BBB. A further objective of our study was to investigate interactions of QND and PSC-833 (a clinically relevant P-gp inhibitor) to determine if they can serve as a reference probe substrate/inhibitor combination in assessing investigational drugs for their interactions with P-gp at the BBB in vitro and in vivo. The assay system consisted of in vitro and in vivo elements: (i) ATPase assay, (ii) MDCKII-MDR1 monolayer assay, (iii) primary rat brain endothelial cell (RBEC) monolayer assay and (iv) dual- and triple-probe microdialysis studies in anesthetized and awake rats.
In membranes prepared from insect cells overexpressing human P-gp QND stimulated the vanadate sensitive ATPase activity. Both PSC-833 and Ly-335979 antagonized the stimulatory effect of QND as expected (Fig1A and D).
Figure 1. Interaction of quinidine with P-gp in vitro. Activation of vanadate sensitive P-gp ATPase by QND (A) and its modulation by P-gp inhibitors (PSC-833 and LY-335979) (D). Vectorial transport of QND in monolayers from human MDR1 expressing MDCKII and parental cells (panel B) and its modulation by the inhibitors (E). Vectorial transport of QND in primary RBEC monolayer (C) and its inhibition by PSC-833 and LY-335979 at 15 min incubation (F).
In MDCKII-MDR1 monolayers expressing human MDR1, QND showed appropriate efflux ratio (ER>2). The vectorial transport of QND was inhibited by PSC-833 and by Ly-335979 (Fig 1B, E).
Brain endothelial cell monolayer assays were carried out using primary cells isolated from both rat and mouse. In RBEC monolayer assay a 1.5- to 2.0-fold efflux ratio was found for QND transcellular transport depending on the length of incubation time (15, 30, 60 min). Vectorial transport of QND was inhibited by PSC-833 and Ly-335979 with similar potency (Fig 1 C, F). Similar results were gained with MBEC (data not shown). In RBEC using digoxin a reasonable efflux ratio was observed only at 15 min incubation while it was decreased at later time points (data not shown).
Microdialysis technique is the gold standard for assessing the concentration of pharmacologically active, free form of compounds in the target tissue. In anesthetized rats QND was administered intravenously and its unbound levels were determined in brain and blood by dual-probe microdialysis. The AUC (area under the curve) of QND was calculated in brain and blood dialysate samples and the AUCbrain/AUCblood ratio was determined. In control animals the ratio was about 0.3 (Fig.2 Panel A and B), while after i.v. administration of PSC-833 the brain to blood ratio increased to appr. 1.0 (Fig.2 Panel C). Similar results were observed in mouse microdialysis experiments (data not shown).
Figure 2. Concentration– time profiles of QND in dialysate samples from brain and blood. In the absolute control group (panel A) the animals received vehicle and QND. In the second group (panel B) the animals received vehicle for PSC-833 and QND. In the third group (panel C) PSC-833 was given as a pre-treatment and also as a co-treatment together with QND.
Although digoxin is one of the recommended probe substrate for P-gp (FDA Draft Guidance, 2006) for in vitro assessments, to date, no data on DGX from intracerebral microdialysis experiments has been published. In a pilot study we administered DGX i.v., butno detectable levels of DGX in brain dialysate samples was observed (data not shown).
Quinidine is a good probe substrate for studying P-gp function at the BBB since it works well in in vitro assays with different complexity, and also in vivo in microdialysis studies in rats and mice while meeting the the criteria (Ma et al., 2010) of specificity, sensitivity, and technical feasibility. Even more importantly our results show that quinidine and PSC-833 can serve as an excellent P-gp-specific probe substrate/inhibitor combination applicable to several assay systems both in vitro and in vivo.
The BBB-package of SOLVO Biotechnology is being extended by application of primary mouse brain endothelial cell monolayer assay (MBEC) and a microdialysis study-package in anesthetized and non-anesthetized mice. With increasing number of humanized transgenic mice (Hasegawa et al., 2011) including transporter humanized mouse (Patterson et al., 2008; Jiang et al., 2011) available an integrated test system with mouse microdialysis experimentation becomes more and more important to predict drug disposition and drug-drug interactions in humans.
Eyal S, Hsiao P, Unadkat JD. Drug interactions at the blood-brain barrier: Fact or fantasy? Pharmacol Ther. 2009;123:80-104
FDA Draft Guidance: Drug Interaction Studies, Study Design, Data Analysis, and Implications for Dosing and Labeling, 2006
Garberg P, Ball M, Borg N, Cecchelli R, Fenart L, Hurst RD, Lindmark T, Mabondzo A, Nilsson JE, Raub TJ, Stanimirovic D, Terasaki T, Oberg JO, Osterberg T. In vitro models for the blood-brain barrier. Toxicol In Vitro. 2005 Apr;19(3):299-334.
Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9:215-36.
Hasegawa M, Kapelyukh Y, Tahara H, Seibler J, Rode A, Krueger S, Lee DN, Wolf CR, Scheer N. Quantitative prediction of human pregnane X receptor and cytochrome P450 3A4 mediated drug-drug interaction in a novel multiple humanized mouse line. Mol Pharmacol. 2011;80:518-28.
Ishiwata K, Kawamura K, Yanai K, Hendrikse NH. In vivoevaluation of P-glycoprotein modulation of 8 PET radioligands used clinically.J Nucl Med. 2007;48:81-7.
Jiang XL, Gonzalez FJ, Yu AM. Drug-metabolizing enzyme, transporter, and nuclear receptor genetically modified mouse models. Drug Metab Rev. 2011 Feb;43(1):27-40. Epub 2010 Sep 21.
Kusuhara H, Suzuki H, Terasaki T, Kakee A, Lemaire M, Sugiyama Y. P-glycoprotein mediates the efflux of quinidine across the blood-brain barrier. J Pharmacol Exp Ther. 1997;283:574-80.
Ma JD, Tsunoda SM, Bertino JS Jr, Trivedi M, Beale KK, Nafziger AN. Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation. Clin Pharmacokinetic. 2010;49:223-37.
Miyama T, Takanaga H, Matsuo H, Yamano K, Yamamoto K, Iga T, Naito M, Tsuruo T, Ishizuka H, Kawahara Y, Sawada Y. P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier. Antimicrob Agents Chemother. 1998;42:1738-44.
von Moltke LL, Granda BW, Grassi JM , Preroff MD, Vishnuvardhan D, Greenblatt DJ. Interaction of triazolam and ketoconazole in P-glycoprotein-deficient mice. Drug metabolism and disposition: the biological fate of chemicals. Drug Metab Dispos. 2004; 32:800-4.
Patterson D, Graham C, Cherian C, Matherly LH. A humanized mouse model for the reduced folate carrier. Mol Genet Metab. 2008 Feb;93(2):95-103. Epub 2007 Nov 5.
Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS. Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001;299:620-8.
Sasongko L, Link JM, Mankoff DA, Yang X, Collier AC, Shoner SC, Unadkat JD. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clinical pharmacology and therapeutics. Clin Pharmacol Ther. 2005;77:503-14.
Sziráki I, Erdő F, Beéry E, Molnár PM, Fazakas C, Wilhelm I, Makai I, Kis E, Herédi-Szabó K, Abonyi T, Krizbai I, Tóth GK, Krajcsi P. Quinidine as an ABCB1 Probe for Testing Drug Interactions at the Blood-Brain Barrier: An In Vitro In Vivo Correlation Study. J Biomol Screen. 2011;16:886-94.
Zhang L, Zhang YD, Zhao P, Huang SM. Predicting drug-drug interactions: an FDA perspective. AAPS J. 2009;11:300-6.